Trials / Completed
CompletedNCT03001076
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Bempedoic Acid (ETC 1002) 180 mg/Day as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 269 (actual)
- Sponsor
- Esperion Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if bempedoic acid (ETC-1002) added-on to ezetimibe therapy is effective and safe versus placebo in patients with elevated LDL cholesterol.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bempedoic acid | bempedoic acid 180 mg tablet |
| DRUG | Ezetimibe | ezetimibe 10 mg tablet |
| OTHER | Placebo | matching placebo tablet |
Timeline
- Start date
- 2016-11-29
- Primary completion
- 2018-01-11
- Completion
- 2018-02-12
- First posted
- 2016-12-22
- Last updated
- 2020-05-11
- Results posted
- 2020-04-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03001076. Inclusion in this directory is not an endorsement.